{"O": 0, "B-人均收入": 1, "I-人均收入": 2, "E-人均收入": 3, "S-人均收入": 4, "B-存货": 5, "I-存货": 6, "E-存货": 7, "S-存货": 8, "B-IND申报数": 9, "I-IND申报数": 10, "E-IND申报数": 11, "S-IND申报数": 12, "B-投融资情况": 13, "I-投融资情况": 14, "E-投融资情况": 15, "S-投融资情况": 16, "B-CR5": 17, "I-CR5": 18, "E-CR5": 19, "S-CR5": 20, "B-利润增长": 21, "I-利润增长": 22, "E-利润增长": 23, "S-利润增长": 24, "B-研发费用率": 25, "I-研发费用率": 26, "E-研发费用率": 27, "S-研发费用率": 28, "B-PEG": 29, "I-PEG": 30, "E-PEG": 31, "S-PEG": 32, "B-临床试验数量": 33, "I-临床试验数量": 34, "E-临床试验数量": 35, "S-临床试验数量": 36, "B-行业公司": 37, "I-行业公司": 38, "E-行业公司": 39, "S-行业公司": 40, "B-市值": 41, "I-市值": 42, "E-市值": 43, "S-市值": 44, "B-现金流": 45, "I-现金流": 46, "E-现金流": 47, "S-现金流": 48, "B-扣非净利润增速": 49, "I-扣非净利润增速": 50, "E-扣非净利润增速": 51, "S-扣非净利润增速": 52, "B-PE": 53, "I-PE": 54, "E-PE": 55, "S-PE": 56, "B-地点范围": 57, "I-地点范围": 58, "E-地点范围": 59, "S-地点范围": 60, "B-扣非净利润": 61, "I-扣非净利润": 62, "E-扣非净利润": 63, "S-扣非净利润": 64, "B-行业趋势": 65, "I-行业趋势": 66, "E-行业趋势": 67, "S-行业趋势": 68, "B-新药获批数": 69, "I-新药获批数": 70, "E-新药获批数": 71, "S-新药获批数": 72, "B-利润": 73, "I-利润": 74, "E-利润": 75, "S-利润": 76, "B-固定资产增速": 77, "I-固定资产增速": 78, "E-固定资产增速": 79, "S-固定资产增速": 80, "B-时间连接词": 81, "I-时间连接词": 82, "E-时间连接词": 83, "S-时间连接词": 84, "B-研发费用": 85, "I-研发费用": 86, "E-研发费用": 87, "S-研发费用": 88, "B-行业供给": 89, "I-行业供给": 90, "E-行业供给": 91, "S-行业供给": 92, "B-营业收入": 93, "I-营业收入": 94, "E-营业收入": 95, "S-营业收入": 96, "B-员工数量": 97, "I-员工数量": 98, "E-员工数量": 99, "S-员工数量": 100, "B-竞争格局": 101, "I-竞争格局": 102, "E-竞争格局": 103, "S-竞争格局": 104, "B-主营业务": 105, "I-主营业务": 106, "E-主营业务": 107, "S-主营业务": 108, "B-市场集中度": 109, "I-市场集中度": 110, "E-市场集中度": 111, "S-市场集中度": 112, "B-产能": 113, "I-产能": 114, "E-产能": 115, "S-产能": 116, "B-主要玩家": 117, "I-主要玩家": 118, "E-主要玩家": 119, "S-主要玩家": 120, "B-CAGR": 121, "I-CAGR": 122, "E-CAGR": 123, "S-CAGR": 124, "B-属性值": 125, "I-属性值": 126, "E-属性值": 127, "S-属性值": 128, "B-投融资事件数": 129, "I-投融资事件数": 130, "E-投融资事件数": 131, "S-投融资事件数": 132, "B-行业": 133, "I-行业": 134, "E-行业": 135, "S-行业": 136, "B-行业需求": 137, "I-行业需求": 138, "E-行业需求": 139, "S-行业需求": 140, "B-假设情形": 141, "I-假设情形": 142, "E-假设情形": 143, "S-假设情形": 144, "B-财务情况": 145, "I-财务情况": 146, "E-财务情况": 147, "S-财务情况": 148, "B-CAPEX资本开支": 149, "I-CAPEX资本开支": 150, "E-CAPEX资本开支": 151, "S-CAPEX资本开支": 152, "B-合同负债": 153, "I-合同负债": 154, "E-合同负债": 155, "S-合同负债": 156, "B-归母净利润增速": 157, "I-归母净利润增速": 158, "E-归母净利润增速": 159, "S-归母净利润增速": 160, "B-ROE净资产回报率": 161, "I-ROE净资产回报率": 162, "E-ROE净资产回报率": 163, "S-ROE净资产回报率": 164, "B-业务指标情况": 165, "I-业务指标情况": 166, "E-业务指标情况": 167, "S-业务指标情况": 168, "B-CR10": 169, "I-CR10": 170, "E-CR10": 171, "S-CR10": 172, "B-公司": 173, "I-公司": 174, "E-公司": 175, "S-公司": 176, "B-人均利润": 177, "I-人均利润": 178, "E-人均利润": 179, "S-人均利润": 180, "B-属性连接词": 181, "I-属性连接词": 182, "E-属性连接词": 183, "S-属性连接词": 184, "B-新签订单": 185, "I-新签订单": 186, "E-新签订单": 187, "S-新签订单": 188, "B-外包率": 189, "I-外包率": 190, "E-外包率": 191, "S-外包率": 192, "B-收入增速": 193, "I-收入增速": 194, "E-收入增速": 195, "S-收入增速": 196, "B-营收占比": 197, "I-营收占比": 198, "E-营收占比": 199, "S-营收占比": 200, "B-龙头企业": 201, "I-龙头企业": 202, "E-龙头企业": 203, "S-龙头企业": 204, "B-客户数量": 205, "I-客户数量": 206, "E-客户数量": 207, "S-客户数量": 208, "B-市场规模": 209, "I-市场规模": 210, "E-市场规模": 211, "S-市场规模": 212, "B-在手订单": 213, "I-在手订单": 214, "E-在手订单": 215, "S-在手订单": 216, "B-投融资金额": 217, "I-投融资金额": 218, "E-投融资金额": 219, "S-投融资金额": 220, "B-FDA新药获批数": 221, "I-FDA新药获批数": 222, "E-FDA新药获批数": 223, "S-FDA新药获批数": 224, "B-ROIC资本回报率": 225, "I-ROIC资本回报率": 226, "E-ROIC资本回报率": 227, "S-ROIC资本回报率": 228, "B-固定资产": 229, "I-固定资产": 230, "E-固定资产": 231, "S-固定资产": 232, "B-时间范围": 233, "I-时间范围": 234, "E-时间范围": 235, "S-时间范围": 236, "B-毛利": 237, "I-毛利": 238, "E-毛利": 239, "S-毛利": 240, "B-归母净利润": 241, "I-归母净利润": 242, "E-归母净利润": 243, "S-归母净利润": 244, "B-业绩": 245, "I-业绩": 246, "E-业绩": 247, "S-业绩": 248, "B-营收增长": 249, "I-营收增长": 250, "E-营收增长": 251, "S-营收增长": 252, "B-市场份额": 253, "I-市场份额": 254, "E-市场份额": 255, "S-市场份额": 256}